Abilify Discmelt

Abilify Discmelt Dosage/Direction for Use

aripiprazole

Manufacturer:

Otsuka
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Dosage/Direction for Use
Usual Dose: Schizophrenia: Adults: Recommended Starting and Target Dose: 10 or 15 mg once daily without regard to meals.
Abilify Discmelt has been systematically evaluated and shown to be effective in a dose range of 10-30 mg daily. However, doses higher than 10 or 15 mg daily were not more effective than 10 or 15 mg daily. Dosage increases should not be made 2 weeks before the time needed to achieve steady state.
Adolescents: Starting Daily Dose: 2 mg titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg daily dose was not shown to be more efficacious than the 10 mg daily dose.
Bipolar Disorder: Adults: Starting Dose: 30 mg once daily without regard to meals. A dose of 30 mg daily was found to be effective when administered as the tablet formulation. Approximately 15% of patients had their dose decreased to 15 mg based on tolerability assessment. The safety of doses above 30 mg daily has not been evaluated in clinical trials.
Children and Adolescents: The efficacy of aripiprazole has been established in the treatment of children and adolescent patients 10-17 years with bipolar I disorder at doses of 10 or 30 mg daily. Recommended Target Dose: 10 mg daily. Starting Daily Dose: 2 mg daily titrated to 5 mg daily after 2 days and to the target dose of 10 mg after 2 additional days.
Subsequent dose increases should be administered without regard to meals.
Major Depressive Disorder: Adults: Recommended Starting Dose: Adjunctive Treatment for Patients Taking an Antidepressants: 2-5 mg daily. The efficacy as an adjunctive therapy was established within a dose range of 2-15 mg daily.
Dose adjustment of up to 5 mg daily should occur gradually at intervals of no less than 1 week.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in